Physician profile
Bryan K Chen
NPI 1518919703
$10,886.97
in general payments reported to CMS, 2019-2025
31 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $838 · 2021: $1,517 · 2022: $1,395 · 2023: $2,022 · 2024: $1,885 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,949.51 |
| Education | $389.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,702.41 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,320.21 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $932.34 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $881.63 | 2019-2025 | |
| Genzyme Corporation | $831.74 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $723.14 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $687.75 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $448.74 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $398.12 | 2019-2023 | Jublia, Duobrii, Arazlo |
| Ucb, INC. | $381.62 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $354.31 | 2023-2025 | Zoryve |
| Almirall LLC | $284.75 | 2019-2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $277.42 | 2020-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $251.48 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $247.63 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $213.42 | 2019-2025 | Epsolay, Twyneo, Aklief |
| Dermavant Sciences, INC. | $185.51 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $163.08 | 2019-2025 | |
| Celgene Corporation | $112.43 | 2019 | |
| Dermira, INC. | $105.50 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $92.38 | 2021 | |
| Allergan, INC. | $76.32 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $31.31 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $30.12 | 2019 | |
| Genentech USA, INC. | $28.20 | 2024 | Erivedge |
| Promius Pharma LLC | $25.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.33 | 2024 | Spevigo |
| Mylan Pharmaceuticals INC. | $20.05 | 2019 | |
| Aclaris Therapeutics, INC. | $19.80 | 2019 | |
| Mission Pharmacal Company | $18.36 | 2019 | |
| Journey Medical Corporation | $17.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.